下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認(rèn)領(lǐng)
文檔簡介
1、 HYPERLINK https:/www.MedChemE/Targets/Fatty Acid Synthase (FAS).html Fatty HYPERLINK https:/www.MedChemE/Targets/Fatty Acid Synthase (FAS).html HYPERLINK https:/www.MedChemE/Targets/Fatty Acid Synthase (FAS).html Acid HYPERLINK https:/www.MedChemE/Targets/Fatty Acid Synthase (FAS).html HYPERLINK ht
2、tps:/www.MedChemE/Targets/Fatty Acid Synthase (FAS).html Synthase HYPERLINK https:/www.MedChemE/Targets/Fatty Acid Synthase (FAS).html HYPERLINK https:/www.MedChemE/Targets/Fatty Acid Synthase (FAS).html (FASN)Fatty Acid Synthase (FASN) is a multifunctional homodimeric enzyme protein, and it is the
3、major enzyme required for the anabolicconversion of dietary carbohydrates to fatty acids. Fatty acid synthase catalyzes the conversion of acetyl-CoA and malonyl-CoA, inthe presence of NADPH, into long-chain saturated fatty acids.Human fatty acid synthase is a large homodimeric multifunctional enzyme
4、 that synthesizes palmitic acid. The unique carboxylterminal thioesterase domain of fatty acid synthase hydrolyzes the growing fatty acid chain and plays a critical role in regulating thechain length of fatty acid released. Also, the up-regulation of human fatty acid synthase in a variety of cancer
5、makes thethioesterase a candidate target for therapeutic treatment.www.MedChemE 1 HYPERLINK https:/www.MedChemE/Targets/Fatty Acid Synthase (FAS).html Fatty HYPERLINK https:/www.MedChemE/Targets/Fatty Acid Synthase (FAS).html HYPERLINK https:/www.MedChemE/Targets/Fatty Acid Synthase (FAS).html Acid
6、HYPERLINK https:/www.MedChemE/Targets/Fatty Acid Synthase (FAS).html HYPERLINK https:/www.MedChemE/Targets/Fatty Acid Synthase (FAS).html Synthase HYPERLINK https:/www.MedChemE/Targets/Fatty Acid Synthase (FAS).html HYPERLINK https:/www.MedChemE/Targets/Fatty Acid Synthase (FAS).html (FASN) HYPERLIN
7、K https:/www.MedChemE/Targets/Fatty Acid Synthase (FAS).html HYPERLINK https:/www.MedChemE/Targets/Fatty Acid Synthase (FAS).html Inhibitors HYPERLINK https:/www.MedChemE/Targets/Fatty Acid Synthase (FAS).html HYPERLINK https:/www.MedChemE/Targets/Fatty Acid Synthase (FAS).html & HYPERLINK https:/ww
8、w.MedChemE/Targets/Fatty Acid Synthase (FAS).html HYPERLINK https:/www.MedChemE/Targets/Fatty Acid Synthase (FAS).html Modulators HYPERLINK https:/www.MedChemE/albaspidin-ap.html Albaspidin HYPERLINK https:/www.MedChemE/albaspidin-ap.html HYPERLINK https:/www.MedChemE/albaspidin-ap.html APCat. No.:
9、HY-N0200 HYPERLINK https:/www.MedChemE/Betulin.html Betulin(Trochol) Cat. No.: HY-N0083Albaspidin AP inhibits fatty acid synthase (FAS)with an IC value of 71.7 M. Fatty acid synthase50(FAS) is emerging as a potential therapeutictarget for cancer and obesity.Betulin (Trochol), is a sterol regulatorye
10、lement-binding protein (SREBP) inhibitor with anIC of 14.5 M in K562 cell line.50Purity: 98%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 25 mgPurity: 98.0%Clinical Data: No Development ReportedSize: 50 mg, 100 mg, 200 mg HYPERLINK https:/www.MedChemE/bi99179.html BI HYPERLINK https:/www.
11、MedChemE/bi99179.html HYPERLINK https:/www.MedChemE/bi99179.html 99179 HYPERLINK https:/www.MedChemE/bi99179.html HYPERLINK https:/www.MedChemE/C75.html C75Cat. No.: HY-16100 Cat. No.: HY-12364BI 99179 is a potent and selective type I fattyacid synthase (FAS) inhibitor with an IC of 7950nM. BI 99179
12、 is a tool compound suitable for thein vivo validation of FAS as a target for lipidmetabolism related diseases.C75 is a synthetic fatty-acid synthase (FASN)inhibitor; inhibits prostate cancer cells PC3 withan IC50 of 35 M. C75 is a potent CPT1Aactivator.Purity: 99.78%Clinical Data: No Development Re
13、portedSize: 5 mg, 10 mg, 50 mg, 100 mgPurity: 99.91%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mg HYPERLINK https:/www.MedChemE/Cerulenin.html CeruleninCat. No.: HY-A0210 HYPERLINK https:/www.MedChemE/fasn-in-2.html Denifanstat(TVB-2640; FASN-IN-2; ASC-40) Cat. No.: HY-1
14、12829Cerulenin, a potent, natural inhibitor of fattyacid synthase (FASN), is an epoxide produced bythe fungus Cephalosporium caeruleus. Cerulenininhibits topoisomerase I catalytic activity andaugments SN-38-induced apoptosis. Cerulenin hasantifungal and antitumor activies.Denifanstat (TVB-2640) is a
15、n orally active andpotent Fatty Acid Synthase (FASN) inhibitor withan IC50 of 0.052 M and an EC50 of 0.072 M.Denifanstat has the potential for fatty liverdisease and cancer research.Purity: 98.0%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mgPurity: 99.69%Clinical Data: Phase 2Size: 10
16、mM 1 mL, 5 mg, 10 mg, 50 mg HYPERLINK https:/www.MedChemE/desoxyrhaponticin.html Desoxyrhaponticin HYPERLINK https:/www.MedChemE/desoxyrhaponticin.html HYPERLINK https:/www.MedChemE/dihydrocurcumin.html DihydrocurcuminCat. No.: HY-N2486 Cat. No.: HY-N1967Desoxyrhaponticin is a stilbene glycoside fro
17、m theTibetan nutritional food Rheum tanguticumMaxim. Desoxyrhaponticin is a Fatty acid synthase(FASN) inhibitor, and has apoptotic effect onhuman cancer cells.Dihydrocurcumin, a major metabolites of curcumin,reduces lipid accumulation and oxidative stress.Purity: 99.80%Clinical Data: No Development
18、ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mgPurity: 99.77%Clinical Data: No Development ReportedSize: 5 mg, 10 mg HYPERLINK https:/www.MedChemE/fasn-in-1.html FASN-IN-1 HYPERLINK https:/www.MedChemE/fasn-in-1.html HYPERLINK https:/www.MedChemE/Heterocyclic_modulators_1.html FASN-IN-3Cat. No.: HY-111
19、777 Cat. No.: HY-U00436FASN-IN-1 is a fatty acid synthase (FASN)inhibitor extracted from patent WO2015134790A1,compound 56.FASN-IN-3 is a fatty acid synthase (FASN)inhibitor extracted from patent US20170119786A1,compound 242A.Purity: 99.62%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg
20、, 10 mg, 50 mg, 100 mgPurity: 98.17%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg2 Tel: 609-228-6898 Fax: 609-228-5909 Email: salesMedChemE HYPERLINK https:/www.MedChemE/FAS-IN-1.html FASN-IN-4 HYPERLINK https:/www.MedChemE/FAS-IN-1.html HYPERLINK https:/w
21、ww.MedChemE/FAS-IN-1-Tosylate.html FASN-IN-4 HYPERLINK https:/www.MedChemE/FAS-IN-1-Tosylate.html HYPERLINK https:/www.MedChemE/FAS-IN-1-Tosylate.html tosylateCat. No.: HY-12648 Cat. No.: HY-12648AFASN-IN-4 is a potent inhibitor of fatty acidsynthase (FASN) with an IC of 10 nM50(WO2012064642A1, comp
22、ound 29). FASN-IN-4 alsoinhibits SARS-CoV-2 with an EC of 18.6nM.50FASN-IN-4 tosylate is a potent inhibitor of fattyacid synthase (FASN) with an IC of 10 nM50(WO2012064642A1, compound 29). FASN-IN-4 tosylatealso inhibits SARS-CoV-2 with an EC of5018.6nM.Purity: 99.21%Clinical Data: No Development Re
23、portedSize: 10 mM 1 mL, 2 mgPurity: 98.63%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 2 mg, 5 mg, 10 mg, 50 mg HYPERLINK https:/www.MedChemE/fasn-in-5.html FASN-IN-5Cat. No.: HY-145809 HYPERLINK https:/www.MedChemE/Fatostatin-A.html Fatostatin(125B11) Cat. No.: HY-14452FASN-IN-5 (example
24、 11), a FASN inhibitor, can beused for the research of TH17- or CSF1 -mediateddisease or disorder such as cancer, immunologicaldisorders, and obesity.Fatostatin (125B11), a specific inhibitor ofSREBP activation, impairs the activation ofSREBP-1 and SREBP-2. Fatostatin binds to SCAP(SREBP cleavage-ac
25、tivating protein), and inhibitsthe ER-Golgi translocation of SREBPs.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98.20%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/fatostatin-hydrobromide.html Fato
26、statin HYPERLINK https:/www.MedChemE/fatostatin-hydrobromide.html HYPERLINK https:/www.MedChemE/fatostatin-hydrobromide.html hydrobromide(125B11 hydrobromide) Cat. No.: HY-14452A HYPERLINK https:/www.MedChemE/FGH10019.html FGH10019Cat. No.: HY-16207Fatostatin hydrobromide (125B11 hydrobromide), aspe
27、cific inhibitor of SREBP activation, impairsthe activation of SREBP-1 and SREBP-2. Fatostatinhydrobromide binds to SCAP (SREBPcleavage-activating protein), and inhibits theER-Golgi translocation of SREBPs.FGH10019 is a novel sterol regulatoryelement-binding protein (SREBP) inhibitor withIC of 1 M.50
28、Purity: 99.61%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mgPurity: 99.43%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mg HYPERLINK https:/www.MedChemE/FT113.html FT113 HYPERLINK https:/www.MedChemE/FT113.html HYPERLINK https:/www
29、.MedChemE/HS79.html HS79Cat. No.: HY-111551 Cat. No.: HY-112522FT113 is a potent and orally active fatty acidsynthase (FASN) inhibitor, with an IC of 213 nM50for full-length recombinant human FASN enzyme. Incell-based assay, FT113 blocks FASN activity inBT474 cells (IC , 90 nM).50HS-79 is an enantio
30、mer of Fasnall, which is aselective fatty acid synthase (FASN) inhibitor.HS-79 is able to inhibit the incorporation oftritiated acetate into lipids with an IC of 1.5750M.Purity: 99.61%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mgPurity: 98%Clinical Data: No Devel
31、opment ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/HS80.html HS80 HYPERLINK https:/www.MedChemE/HS80.html HYPERLINK https:/www.MedChemE/ipi-9119.html IPI-9119Cat. No.: HY-112522A Cat. No.: HY-124628HS-80 is an enantiomer of Fasnall, which is aselective fatty acid synthase (FASN) inhibitor
32、.HS-80 is able to inhibit the incorporation oftritiated acetate into lipids with an IC of 7.1350M.IPI-9119 is an orally active, selective andirreversible FASN inhibitor with an IC of 0.350nM in vitro biochemical assay. IPI-9119 inhibitstumor growth of castration-resistant prostatecancer (CRPC) xenog
33、rafts mouse models.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98.13%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mgwww.MedChemE 3 HYPERLINK https:/www.MedChemE/leelamine-hydrochloride.html Leelamine HYPERLINK https:/www.MedChemE
34、/leelamine-hydrochloride.html HYPERLINK https:/www.MedChemE/leelamine-hydrochloride.html hydrochloride HYPERLINK https:/www.MedChemE/leelamine-hydrochloride.html HYPERLINK https:/www.MedChemE/leelamine-d4-hydrochloride.html Leelamine-d4 HYPERLINK https:/www.MedChemE/leelamine-d4-hydrochloride.html H
35、YPERLINK https:/www.MedChemE/leelamine-d4-hydrochloride.html hydrochlorideCat. No.: HY-110028 Cat. No.: HY-110028SLeelamine hydrochloride is a tricyclic diterpenemolecule that is extracted from the bark of pinetrees.Leelamine-d4 hydrochloride is the deuteriumlabeled Leelamine hydrochloride. Leelamin
36、ehydrochloride is a tricyclic diterpene moleculethat is extracted from the bark of pine trees.Purity: 98%Clinical Data:Size: 5 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/lycorine.html Lycorine HYPERLINK https:/www.MedChemE/lycorine.html HYPERLIN
37、K https:/www.MedChemE/Nicodicosapent.html NicodicosapentCat. No.: HY-N0288 Cat. No.: HY-17640Lycorine is a natural alkaloid extracted from theAmaryllidaceae plant. Lycorine is a potent andorally active SCAP inhibitor with a K valued15.24 nM. Lycorine downregulates the SCAP proteinlevel without chang
38、ing its transcription.Nicodicosapent is a fatty acid niacin conjugatethat is also an inhibitor of the sterol regulatoryelement binding protein (SREBP), a key regulatorof cholesterol metabolism proteins such as PCSK9,HMG-CoA reductase, ATP citrate lyase, and NPC1L1.Purity: 98.0%Clinical Data: No Deve
39、lopment ReportedSize: 50 mg, 100 mgPurity: 98.04%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/orlistat.html Orlistat(Tetrahydrolipstatin; Ro-18-0647) Cat. No.: HY-B0218 HYPERLINK https:/www.MedChemE/pedunculoside.html Peduncul
40、osideCat. No.: HY-N0458Orlistat (Tetrahydrolipstatin) is a well-knownirreversible inhibitor of pancreatic and gastriclipases. Orlistat is also an inhibitor of fattyacid synthase (FASN), is used orally forlong-term research ofobesity. Anti-atherosclerotic effect.Pedunculoside exerts lipid-lowering ef
41、fects partlythrough the regulationof lipogenesis and fatty acid-oxidation.Purity: 98.88%Clinical Data: LaunchedSize: 10 mM 1 mL, 100 mg, 200 mg, 500 mgPurity: 99.17%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 20 mg HYPERLINK https:/www.MedChemE/PF429242_dihydrochloride.html PF429242 HYP
42、ERLINK https:/www.MedChemE/PF429242_dihydrochloride.html HYPERLINK https:/www.MedChemE/PF429242_dihydrochloride.html dihydrochloride HYPERLINK https:/www.MedChemE/PF429242_dihydrochloride.html HYPERLINK https:/www.MedChemE/Praeruptorin_B.html Praeruptorin HYPERLINK https:/www.MedChemE/Praeruptorin_B
43、.html HYPERLINK https:/www.MedChemE/Praeruptorin_B.html BCat. No.: HY-13447A(Praeruptorin D) Cat. No.: HY-N0082PF429242 dihydrochloride is a reversible andcompetitive SREBP site 1 protease (S1P)inhibitor with an IC of 175 nM.50Praeruptorin B is an inhibitor of sterolregulatory element-binding protei
44、ns (SREBPs).Purity: 99.32%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mgPurity: 99.95%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 25 mg HYPERLINK https:/www.MedChemE/pseudoprotodioscin.html Pseudoprotodioscin HYPERLINK https:/www.MedChemE/pseud
45、oprotodioscin.html HYPERLINK https:/www.MedChemE/C75-trans.html trans-C75Cat. No.: HY-N0686()-C75) Cat. No.: HY-12364APseudoprotodioscin, a furostanoside, inhibitsSREBP1/2 and microRNA 33a/b levels and reduces thegene expression regarding the synthesis ofcholesterol and triglycerides.trans-C75 ()-C7
46、5) is an enantiomer of C75. C75is a synthetic fatty-acid synthase (FASN)inhibitor.Purity: 98.76%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 20 mgPurity: 99.91%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mg4 Tel: 609-228-6898 Fax: 609-228-5909 Email: salesMedChemE HYPERL
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 2025版借款墊資風(fēng)險控制合作協(xié)議范本3篇
- 2025年度智能電網(wǎng)項目可研咨詢服務(wù)協(xié)議正范文本3篇
- 學(xué)校化糞池維修工程協(xié)議
- 2025版文化旅游項目建議書編制及運營管理合同3篇
- 徒步班組施工合同
- 保險服務(wù)標(biāo)準(zhǔn)化管理辦法
- 通信設(shè)備招投標(biāo)法規(guī)解析
- 電子產(chǎn)品采購招投標(biāo)改進策略
- 商業(yè)廣場施工合作協(xié)議
- 2025年度模具行業(yè)模具設(shè)計與制造質(zhì)量認(rèn)證合同3篇
- 豬場配懷工作安排方案設(shè)計
- GB/T 2-2016緊固件外螺紋零件末端
- GB/T 12467.5-2009金屬材料熔焊質(zhì)量要求第5部分:滿足質(zhì)量要求應(yīng)依據(jù)的標(biāo)準(zhǔn)文件
- GB 17740-1999地震震級的規(guī)定
- 安全生產(chǎn)事故舉報獎勵制度
- 冠心病健康教育完整版課件
- 永久避難硐室安裝施工組織措施
- 元旦節(jié)前安全教育培訓(xùn)-教學(xué)課件
- 國家開放大學(xué)《理工英語1》單元自測8試題答案
- 芯片工藝流程課件1
- 人教版八年級下冊生物期末測試卷帶答案
評論
0/150
提交評論